Key Points
- Insider sale: Salvatore Privitera sold 3,657 AtriCure shares at an average price of $55, generating $201,135. The transaction was made under a pre-arranged Rule 10b5-1 plan, leaving him with 147,264 shares.
- Financial performance: AtriCure reported quarterly earnings of $0.18 per share and revenue of $153.6 million, exceeding analysts’ revenue expectations. The company guided to fiscal 2026 EPS of $0.24–$0.32.
- Market outlook: Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and a $52 price target, while institutional investors own 99.11% of the company’s stock.
AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) insider Salvatore Privitera sold 3,657 shares of AtriCure stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $55.00, for a total transaction of $201,135.00. Following the completion of the sale, the insider owned 147,264 shares in the company, valued at approximately $8,099,520. This represents a 2.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Salvatore Privitera also recently made the following trade(s):
- On Wednesday, September 2nd, Salvatore Privitera sold 7,763 shares of AtriCure stock. The shares were sold at an average price of $52.50, for a total transaction of $407,557.50.
AtriCure Price Performance
NASDAQ ATRC opened at $52.96 on Friday. AtriCure, Inc. has a 52 week low of $25.36 and a 52 week high of $55.72. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. The stock has a market cap of $2.69 billion, a price-to-earnings ratio of 252.20 and a beta of 1.26. The company has a 50-day moving average price of $41.96 and a two-hundred day moving average price of $33.40.
AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The company had revenue of $153.60 million for the quarter, compared to analysts' expectations of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter in the previous year, the company posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Analysts forecast that AtriCure, Inc. will post 0.29 EPS for the current year.
Institutional Trading of AtriCure
A number of hedge funds and other institutional investors have recently modified their holdings of ATRC. Geneos Wealth Management Inc. bought a new position in AtriCure during the second quarter valued at about $37,000. Harbor Investment Advisory LLC acquired a new position in AtriCure during the second quarter worth about $40,000. Allworth Financial LP bought a new stake in AtriCure in the second quarter worth about $43,000. Integrated Wealth Concepts LLC bought a new stake in AtriCure in the second quarter worth about $46,000. Finally, Smartleaf Asset Management LLC lifted its holdings in AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company's stock valued at $46,000 after acquiring an additional 429 shares during the last quarter. Institutional investors own 99.11% of the company's stock.
Analyst Ratings Changes
Several analysts have weighed in on the company. BTIG Research lifted their target price on AtriCure from $45.00 to $55.00 and gave the company a "buy" rating in a research note on Monday, August 24th. Piper Sandler increased their price target on AtriCure from $50.00 to $60.00 and gave the stock an "overweight" rating in a research note on Thursday, August 27th. UBS Group lowered their price target on AtriCure from $55.00 to $50.00 and set a "buy" rating on the stock in a report on Tuesday, July 28th. Needham & Company LLC lifted their price objective on shares of AtriCure from $45.00 to $64.00 and gave the company a "buy" rating in a research note on Wednesday, September 2nd. Finally, Zacks Research lowered shares of AtriCure from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $52.00.
Read Our Latest Research Report on ATRC
About AtriCure
(
Get Free Report)
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
